Lawrence, KS, United States

University of Kansas

www.ku.edu
Lawrence, KS, United States

The University of Kansas is a public research university and the largest and oldest public university in the U.S. state of Kansas. KU campuses are located in Lawrence, Wichita, Overland Park, Salina, and Kansas City, Kansas, with the main campus located in Lawrence on Mount Oread, the highest location in Lawrence. The university was opened in 1866, under a charter granted by the Kansas Legislature in 1864 following enabling legislation passed in 1863 under the Kansas Constitution.The university's Medical Center and University Hospital are located in Kansas City, Kansas. The Edwards Campus is in Overland Park, Kansas, in the Kansas City metropolitan area. There are also educational and research sites in Parsons and Topeka, and branches of the University of Kansas School of Medicine in Wichita and Salina.Enrollment at the Lawrence and Edwards campuses was 23,597 students in fall 2014; an additional 3,371 students were enrolled at the KU Medical Center for a total enrollment of 26,968 students across the three campuses. The university overall employed 2,663 faculty members in fall 2012.The 2014 U.S. News & World Report rankings listed KU as 101st in the category "national universities" and 47th among public universities. The U.S. News & World Report "Americas Best Graduate Schools" rankings have ranked 49 KU programs since 2008, 35 of which are ranked in the top 40 among public university programs. The university is one of the 62 members of the Association of American Universities. Wikipedia.

SEARCH FILTERS
Time filter
Source Type

Patent
University of Kansas | Date: 2017-04-07

A polymeric metal sequestrant providing antibiotic activity is provided. The polymeric metal sequestrant comprises a polyamine polymer covalently coupled to a chelator, wherein the chelator has a benzene ring with more than one hydroxyl group at any position that is free. The polymeric metal sequestrant is effective in inhibiting and preventing bacterial infections and displays synergistic effects in combination with traditional antibiotics.


Patent
University of Kansas and Washington University in St. Louis | Date: 2017-04-05

A mutant HSV-1 (referred to herein as KOS-NA) was generated. KOS-NA contains novel mutations in the UL39 gene, which encodes for a protein that is a large subunit of ribonucleotide reductase (i.e., ICP6). These UL39 mutations were found to alter two amino acids in ICP6 (R950H and L393P) and are responsible for attenuation of KOS-NA in vivo, and resulted in diminished ICP6 protein levels. These novel UL39 mutations regulate the expression and/or stability of ICP6 and severely impact HSV-1 pathogenesis. Mutant HSV viruses containing these mutations appear to protect against HSV infection and can serve as therapeutic vaccines to help combat preexisting HSV infection in infected individuals.


Patent
Silvergate Pharmaceuticals and University of Kansas | Date: 2017-02-15

Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.


Patent
University of Kansas | Date: 2017-05-17

Cyclic tetrapeptide stereochemical isomers of CJ-15,208, pharmaceutical compositions from such cyclic tetrapeptides, and methods of using such pharmaceutical compositions. The cyclic tetrapeptide compounds and pharmaceutical compositions disclosed herein are potent analgesics active in several pain models with generally minimal tolerance and reduced likelihood to induce addiction relative to other known opiates.


Patent
The United States As Represented By The Secretary and University of Kansas | Date: 2017-04-19

Disclosed are compounds of formula (I), formula (II), and formula (III): wherein Ar, R1, A, and X are as defined in the specification. These compounds are antiviral agents and are contemplated for use in the treatment of viral infections, for example, hepatitis C. These compounds are also contemplated for use in treating or preventing cancers.


Patent
University of Kansas | Date: 2017-04-19

Provided herein are compounds of the formulas:. which are 90-kDa heat shock protein inhibitors. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases, including cancer, e.g., cancers of the breast, the prostate, and the head & neck.


Patent
University of Kansas | Date: 2017-01-06

A fluid sensing device includes an outer body, an inner body coupled to the outer body by one or more inner body support struts and extending at least partially out from the outer body, and an aft body disposed at least partially within the outer body at a location aft of the inner body, the aft body being coupled to the outer body by one or more aft body support struts. The inner body includes a hollow interior for housing one or more inner body sensors, and the aft body houses one or more aft body sensors. The fluid sensing device can measure one or more parameters of fluid flow at high angularity, such as total temperature and total pressure, locally and simultaneously, allowing additional fluid parameters, such as local entropy, to be calculated.


Patent
University of Kansas | Date: 2017-03-06

A device for studying protein conformation transformation can include a macroscopic substrate, and chaperonin proteins bound to the substrate, each chaperonin protein being capable of binding to a protein of interest during or after undergoing protein conformation transformation. The device may also include the proteins of interest bound to the substrate, where the substrate is included in a label-free assay system. A method of studying protein conformation transformation can include: providing a macroscopic substrate bound with the chaperonin protein and immersing the chaperonin protein in a study composition having the protein of interest, or include providing a macroscopic substrate bound with the protein of interest; and immersing the protein in a study composition having the chaperonin. Such a method can be done with and without a potential stabilizer in order to determine whether the potential stabilizer stabilizes the protein of interest.


Patent
University of Kansas, University of Louisville and Southern Research Institute | Date: 2017-02-27

The present technology relates to compounds and compositions of Formulas and methods using such compounds. The compounds and compositions described herein may be used in the treatment or prophylaxis of diseases associated with an alphavirus, for example, Venezuelan equine encephalitis virus (VEEV).


Patent
University of Kansas and University of Oregon | Date: 2017-09-13

The present technology relates to compounds of any one of Formula I, II, IIa, III, IV, and/or V as described herein and their tautomers and/or pharmaceutically acceptable salts, compositions, and methods of uses thereof.

Loading University of Kansas collaborators
Loading University of Kansas collaborators